三阴性乳腺癌(triple-negative breast cancer,TNBC)具有组织学分级高、临床分期晚、侵袭性强、易发生转移等特点。由于缺乏有效的治疗靶点,传统化疗仍是TNBC患者主要的治疗选择。作为高度异质性疾病,TNBC需要更为精确的预测生物标志物...三阴性乳腺癌(triple-negative breast cancer,TNBC)具有组织学分级高、临床分期晚、侵袭性强、易发生转移等特点。由于缺乏有效的治疗靶点,传统化疗仍是TNBC患者主要的治疗选择。作为高度异质性疾病,TNBC需要更为精确的预测生物标志物。组学技术的发展及临床试验的实施为辅助化疗预后生物标志物带来新的探索,涵盖基因、蛋白及微环境成分等不同维度,也包括多分子的联合分析应用。本文将对TNBC辅助化疗预后生物标志物及其潜在分子机制与未来发展方向进行综述。展开更多
To the Editor:Tumor immune microenvironment plays a key role in breast cancer development and progression,which determines the long-term survival of breast cancer patients.Recent data have revealed that the applicatio...To the Editor:Tumor immune microenvironment plays a key role in breast cancer development and progression,which determines the long-term survival of breast cancer patients.Recent data have revealed that the application of cancer immunotherapy has some limitations,including generating weak immune responses due to inadequate delivery of immunostimulants to the immune cells.^([1])Thus,current clinical efforts are primarily focused on developing immune-based chemotherapy that can convert non-responders to responders.^([2])Immunogenic cell death(ICD)is a form of regulated cell death that is sufficient to activate an adaptive immune response.展开更多
The extracellular matrix(ECM)serves as signals that regulate specific cell states in tumor tissues.Increasing evidence suggests that extracellular biomechanical force signals are critical in tumor progression.In this ...The extracellular matrix(ECM)serves as signals that regulate specific cell states in tumor tissues.Increasing evidence suggests that extracellular biomechanical force signals are critical in tumor progression.In this study,we aimed to explore the influence of ECM-derived biomechanical force on breast cancer cell status.Experiments were conducted using 3D collagen,fibrinogen.展开更多
Non-small-cell lung cancer(NSCLC)is the primary histopathological subtype of lung cancer and accounts for around 82%of all pulmonary neoplasms[1].Breast cancer susceptibility gene 1(BRCA1)is a tumor suppressor gene th...Non-small-cell lung cancer(NSCLC)is the primary histopathological subtype of lung cancer and accounts for around 82%of all pulmonary neoplasms[1].Breast cancer susceptibility gene 1(BRCA1)is a tumor suppressor gene that regulates cellular responses to stress through DNA damage repair and is frequently mutated in breast and ovarian cancers[2].Furthermore,previous studies have increasingly shown that the expression of BRCA1 and the relevant poly(ADP-ribose)polymerase inhibitors is related to the prognosis and therapeutic response of other tumors,including lung cancer[3,4].However,previous findings on the prognostic value of BRCA1 for NSCLC have been inconsistent or conflicting,which may be attributed to the small number of patients from a single center or disparity in the ratio of patients with lung adenocarcinoma(LUAD)versus squamous cell carcinoma(LUSC)[5].The aim of this study was to determine the prognostic value of BRCA1 in NSCLC and its association with immune infiltration.展开更多
文摘三阴性乳腺癌(triple-negative breast cancer,TNBC)具有组织学分级高、临床分期晚、侵袭性强、易发生转移等特点。由于缺乏有效的治疗靶点,传统化疗仍是TNBC患者主要的治疗选择。作为高度异质性疾病,TNBC需要更为精确的预测生物标志物。组学技术的发展及临床试验的实施为辅助化疗预后生物标志物带来新的探索,涵盖基因、蛋白及微环境成分等不同维度,也包括多分子的联合分析应用。本文将对TNBC辅助化疗预后生物标志物及其潜在分子机制与未来发展方向进行综述。
文摘To the Editor:Tumor immune microenvironment plays a key role in breast cancer development and progression,which determines the long-term survival of breast cancer patients.Recent data have revealed that the application of cancer immunotherapy has some limitations,including generating weak immune responses due to inadequate delivery of immunostimulants to the immune cells.^([1])Thus,current clinical efforts are primarily focused on developing immune-based chemotherapy that can convert non-responders to responders.^([2])Immunogenic cell death(ICD)is a form of regulated cell death that is sufficient to activate an adaptive immune response.
基金This work was supported by following fundings:CAMS Innovation Fund for Medical Sciences(CIFMS)2021-I2M-1-014the National Natural Science Foundation of China(Grant No.81902578,81974098,8197032158)+3 种基金the National key research and development program of China(Grant No.2017YFC0908003,2017YFC0908004)the Project of Health Commission of Sichuan Province(20PJ062)Post-doctoral Science Research Foundation of Sichuan University(2020SCU12041)Post-Doctor Research Project,West China Hospital,Sichuan University(2018HXBH084).
文摘The extracellular matrix(ECM)serves as signals that regulate specific cell states in tumor tissues.Increasing evidence suggests that extracellular biomechanical force signals are critical in tumor progression.In this study,we aimed to explore the influence of ECM-derived biomechanical force on breast cancer cell status.Experiments were conducted using 3D collagen,fibrinogen.
基金CAMS Innovation Fund for Medical Sciences,Grant/Award Number:2021-I2M-1-014。
文摘Non-small-cell lung cancer(NSCLC)is the primary histopathological subtype of lung cancer and accounts for around 82%of all pulmonary neoplasms[1].Breast cancer susceptibility gene 1(BRCA1)is a tumor suppressor gene that regulates cellular responses to stress through DNA damage repair and is frequently mutated in breast and ovarian cancers[2].Furthermore,previous studies have increasingly shown that the expression of BRCA1 and the relevant poly(ADP-ribose)polymerase inhibitors is related to the prognosis and therapeutic response of other tumors,including lung cancer[3,4].However,previous findings on the prognostic value of BRCA1 for NSCLC have been inconsistent or conflicting,which may be attributed to the small number of patients from a single center or disparity in the ratio of patients with lung adenocarcinoma(LUAD)versus squamous cell carcinoma(LUSC)[5].The aim of this study was to determine the prognostic value of BRCA1 in NSCLC and its association with immune infiltration.
